Natalia Tovar

Natalia Tovar

Auto-generated profile, based on publicly available information

Natalia Tovar

Hospital Clínic, University of Barcelona 14 Barcelona

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
RJRaquel Jiménez-Segura
Raquel Jiménez-Segura
LRLaura Rosiñol
Laura Rosiñol
MCMa Teresa Cibeira
Ma Teresa Cibeira
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
NTNatalia Tovar
Natalia Tovar
Joan BladéJoan Bladé
Joan Bladé
From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal –PPs- 17.6%, extramedullary –EMPs-1.9%). Patients with Ps had lower serum M-protein and less advanced ISS stage than those without. At first relapse, 192 out of 967 patients (19.8%) developed Ps (PPs 14.6%, EMPs 5.1%). The only factor associated with Ps at relapse was the presence of Ps at diagnosis (46% vs 13%, p < 0.00001) with no impact with exposure to novel drugs or previous autologous stem-cell transplantation (ASCT). The median overall survival (OS) was 45, 44 and 20 months for patients without Ps, PPs and EMPs, respectively (p = 0.013). Patients with PPs who underwent ASCT had similar OS than those without Ps (98 vs. 113 months) and significantly longer than those with EMPs (98 vs 47 months, p = 0.006). In patients non-eligible for ASCT the presence of PPs or EMPs was associated with shorter OS compared with patients without Ps (32 vs. 24 vs. 6 months, p = 0.009). In the relapsed setting, a significant survival benefit was observed beyond the year 2000, but still with significant differences among patients without Ps, PPs and EMPs (37 vs 22 vs 16 months, p = 0.003). Importantly, rescue therapy with combinations of proteasome-inhibitors plus immunomodulatory drugs was associated with prolonged OS from first relapse (over 6 years), even in patients with EMPs.

11 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AOAina Oliver-Caldes
Aina Oliver-Caldes
MEMarta Español-Rego
Marta Español-Rego
AZAintzane Zabaleta
Aintzane Zabaleta
VGVerónica González-Calle
Verónica González-Calle
SNSergio Navarro-Velázquez
Sergio Navarro-Velázquez
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Purpose: B-cell maturation antigen (BCMA)-chimeric antigen receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated with CART therapy might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers and resistance mechanisms need to be identified and addressed to improve efficacy and patient selection. Here, we present clinical and ancillary results of the 60 patients treated with the academic BCMA-CART, ARI0002h, in the CARTBCMA-HCB-01 trial. Patients and Methods: We collected apheresis, final product, peripheral blood and bone marrow samples before and after infusion. We assessed BCMA, T-cell subsets, CART kinetics and antibodies, B-cell aplasia, cytokines, and measurable residual disease by next-generation flow cytometry, and correlated these to clinical outcomes. Results: At cut-off date March 17, 2023, with a median follow-up of 23.1 months (95% CI, 9.2–37.1), overall response rate in the first 3 months was 95% [95% confidence interval (CI), 89.5–100]; cytokine release syndrome (CRS) was observed in 90% of patients (5% grades ≥3) and grade 1 immune effector cell-associated neurotoxicity syndrome was reported in 2 patients (3%). Median progression-free survival was 15.8 months (95% CI, 11.5–22.4). Surface BCMA was not predictive of response or survival, but soluble BCMA correlated with worse clinical outcomes and CRS severity. Activation marker HLA-DR in the apheresis was associated with longer progression-free survival and increased exhaustion markers correlated with poorer outcomes. ARI0002h kinetics and loss of B-cell aplasia were not predictive of relapse. Conclusions: Despite deep and sustained responses achieved with ARI0002h, we identified several biomarkers that correlate with poor outcomes.

7 October 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
APArturo Pereira
Arturo Pereira
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
MCMaria Teresa Cibeira
Maria Teresa Cibeira
NTNatalia Tovar
Natalia Tovar
Joan BladéJoan Bladé
Joan Bladé

26 May 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
ADAnna De Daniel
Anna De Daniel
APArturo Pereira
Arturo Pereira
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
NTNatalia Tovar
Natalia Tovar
LRLaura Rosiñol
Laura Rosiñol
The treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies and optimized supportive care. However, the attrition rate (AR), defined as the proportion of patients who die without advancing to the next line of therapy (LOT) after treatment failure, remains a major challenge. To assess how treatment patterns and outcomes have evolved, we analyzed 1,297 MM patients treated between 1980 and 2020, stratified by diagnosis period and age. ARs declined from 38–55% in the 1980s to 15–20% in 2010–2020, but remained high in older patients, with 46.9% of those over 80 unable to proceed beyond first LOT. While progression-free survival gains were primarily observed in the first LOT (15.8 to 24.1 months, p = 0.001), overall survival (OS) improved across all LOTs and age groups, likely due to more effective salvage therapies and supportive care. Achieving a complete response in first-line therapy was associated with a significant OS benefit (4.5 vs. 1.6 years, p < 0.001), underscoring its importance, as many patients, particularly older ones, are less likely to reach subsequent LOTs. Despite advances in MM treatment, patient loss to attrition remains a challenge, highlighting the need for more effective therapies early in the disease course.

27 June 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
OCOriol Cardús
Oriol Cardús
JMJoan Mañé-Pujol
Joan Mañé-Pujol
ABAnthony Battram
Anthony Battram
SVSergi Vaqué-Salsench
Sergi Vaqué-Salsench
CLCarlos Fernández de Larrea
Carlos Fernández de Larrea
Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has revolutionized the prognosis of patients with relapsed/refractory multiple myeloma. Regrettably, despite unprecedented overall response rates achieved with this approach, most patients eventually relapse. One of the primary reasons for this is the complete loss or reduced expression of BCMA on the malignant plasma cell surface. Consequently, new therapeutic targets are under investigation. Another potential therapeutic approach involves the use of CAR T cells targeting two tumor antigens. In this study, we developed and validated a monospecific CAR targeting CD229, which was effective in in vitro and in vivo NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ mouse models with both homogeneous and heterogeneous BCMA expression. Additionally, we created a bicistronic CAR T cell targeting both CD229 and BCMA, which demonstrated efficacy in models with homogeneous BCMA expression, in heterogeneous models featuring small clonal populations with biallelic BCMA deletion, and in cases with reduced BCMA expression both in vivo and in vitro. Regarding “on-target off-tumor toxicity,” no fratricide was observed among CAR T cells, but there was a limited elimination of nonactivated T cells. The immune pressure exerted by anti-CD229 CAR T cells led to the loss of the CD229 antigen expression in some instances. In summary, this work underscores the potential utility of CD229 alone or in combination with BCMA as an immunotherapeutic target in multiple myeloma, especially in cases marked by diminished or absent BCMA expression.

11 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
ELEster Lozano
Ester Lozano
MMMari-Pau Mena
Mari-Pau Mena
GGGloria Garrabou
Gloria Garrabou
OCOriol Cardús
Oriol Cardús
Tània Díaz SánchezTània Díaz Sánchez
Tània Díaz Sánchez
LRLaura Rosiñol
Laura Rosiñol
Purpose: TIGIT blockade in our ex vivo model of bone marrow (BM) reduced the number of malignant plasma cells (PC) in only half of patients with multiple myeloma. Here, we wanted to investigate whether increased expression of TIGIT ligands may inhibit T-cell immune response promoting resistance to TIGIT blockade. Experimental Design: We first characterized the number and phenotype of BM macrophages in different stages of the disease by multiparameter flow cytometry. We assessed the effect of TIGIT ligands on PC survival by performing experiments in the ex vivo BM model and analyzed changes in gene expression by using NanoString technology and real-time PCR. Results: The frequency of BM macrophages was significantly decreased in multiple myeloma, which was accompanied by changes in their immunophenotype. Moreover, we found a higher number of malignant PC in ex vivo BM cells cultured onto the poliovirus receptor (PVR) and nectin-2 compared with control, suggesting that both ligands may support PC survival. In addition, the presence of PVR, but not nectin-2, overcame the therapeutic effect of TIGIT blockade or exogenous IL2. Furthermore, exogenous IL2 increased TIGIT expression on both CD4+ and CD8+ T cells and, indirectly, PVR on BM macrophages. Consistently, PVR reduced the number of cytotoxic T cells and promoted a gene signature with reduced effector molecules. Conclusions: IL2 induced TIGIT on T cells in the BM, in which increased PVR expression resulted in cytotoxic T-cell inhibition, promoting PC survival and resistance to TIGIT blockade.